Armis Identifies the Riskiest Assets Introducing Threats to Global Businesses
5.9.2023 16:00:00 EEST | Business Wire | Press release
Armis, the leading asset visibility and security company, today released new research identifying the riskiest connected assets posing threats to global businesses. Findings highlight risk being introduced to organizations through a variety of connected assets across device classes, emphasizing a need for a comprehensive security strategy to protect an organization’s entire attack surface in real-time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905844605/en/
Source: Data from the Armis Asset Intelligence Engine collected between August 2022 and July 2023.
“Continuing to educate global businesses about the evolving and increased risk being introduced to their attack surface through managed and unmanaged assets is a key mission of ours,” said Nadir Izrael, CTO and Co-Founder of Armis. “This intelligence is crucial to helping organizations defend against malicious cyberattacks. Without it, business, security and IT leaders are in the dark, vulnerable to blind spots that bad actors will seek to exploit.”
Armis’ research, analyzed from the Armis Asset Intelligence Engine, focuses on connected assets with the most attack attempts, weaponized Common Vulnerabilities and Exposures (CVEs) and high-risk ratings to determine the riskiest assets.
Assets With The Highest Number of Attack Attempts
Armis found the top 10 asset types with the highest number of attack attempts were distributed across asset types: IT, OT, IoT, IoMT, Internet of Personal Things (IoPT) and Building Management Systems (BMS). This demonstrates that attackers care more about their potential access to assets rather than the type, reinforcing the need for security teams to account for all physical and virtual assets as part of their security strategy.
Top 10 device types with the highest number of attack attempts:
- Engineering workstations (OT)
- Imaging workstations (IoMT)
- Media players (IoT)
- Personal computers (IT)
- Virtual machines (IT)
- Uninterruptible power supply (UPS) devices (BMS)
- Servers (IT)
- Media writers (IoMT)
- Tablets (IoPT)
- Mobile phones (IoPT)
“Malicious actors are intentionally targeting these assets because they are externally accessible, have an expansive and intricate attack surface and known weaponized CVEs,” said Tom Gol, CTO of Research at Armis. “The potential impact of breaching these assets on businesses and their customers is also a critical factor when it comes to why these have the highest number of attack attempts. Engineering workstations can be connected to all controllers in a factory, imaging workstations will collect private patient data from hospitals and UPSs can serve as an access point to critical infrastructure entities, making all of these attractive targets for malicious actors with varying agendas, like deploying ransomware or causing destruction to society in the case of nation-state attacks. IT leaders need to prioritize asset intelligence cybersecurity and apply patches to mitigate this risk.”
Assets With Unpatched, Weaponized CVEs Vulnerable to Exploitation
Researchers identified a significant number of network-connected assets susceptible to unpatched, weaponized CVEs published before 1/1/2022. Zooming in on the highest percentage of devices of each type that had these CVEs between August 2022 and July 2023, Armis identified the list reflected in Figure A. Unpatched, these assets introduce significant risk to businesses.
Assets with a High-Risk Rating
Armis also examined asset types with the most common high-risk factors:
- Many physical devices on the list that take a long time to replace, such as servers and Programmable Logic Controllers (PLCs), run end-of-life (EOL) or end-of-support (EOS) operating systems. EOL assets are nearing the end of functional life but are still in use, while EOS assets are no longer actively supported or patched for vulnerabilities and security issues by the manufacturer.
- Some assets, including personal computers, demonstrated SMBv1 usage. SMBv1 is a legacy, unencrypted and complicated protocol with vulnerabilities that have been targeted in the infamous Wannacry and NotPetya attacks. Security experts have advised organizations to stop using it completely. Armis found that 74% of organizations today still have at least one asset in their network vulnerable to EternalBlue – an SMBv1 vulnerability.
- Many assets identified in the list exhibited high vulnerability scores, have had threats detected, have been flagged for unencrypted traffic or still have the CDPwn vulnerabilities impacting network infrastructure and VoIPs.
- Half (50%) of pneumatic tube systems were found to have an unsafe software update mechanism.
Additional research from Armis is available on the riskiest OT and ICS devices across critical infrastructure industries as well as the riskiest medical and IoT devices in clinical environments.
Learn more about Armis at www.armis.com.
About Armis
Armis, the leading asset visibility and security company, provides the industry’s first unified asset intelligence platform designed to address the new extended attack surface that connected assets create. Fortune 100 companies trust our real-time and continuous protection to see with full context all managed, unmanaged assets across IT, cloud, IoT devices, medical devices (IoMT), operational technology (OT), industrial control systems (ICS), and 5G. Armis provides passive cyber asset management, risk management, and automated enforcement. Armis is a privately held company and headquartered in California.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905844605/en/
Contact information
Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
